"Behrens et al Izokibep (novel IL-17i fusion protein) in PsA. 16 week RCT demonstrates efficacy. No safety concerns @RheumNow #ACR22 Abstr#1597 https://t.co/PW1ESxcc0U"

izokibep (ABY-035) - Affibody, ACELYRIN

Nov 13, 2022